September 2026

Join WhatsApp Channel 

GPAT caoching
Elanco Animal Health Hiring PV Case Processing Analyst - M.Pharm Fresher Apply
3 September 2026

Elanco Animal Health Hiring PV Case Processing Analyst - M.Pharm Fresher Apply

Basic knowledge of medical terminologies and able to understand common medical terms relevant to pharmacovigilance and adverse event reporting. Elanco Animal Health
Sun Pharma Hiring QC Analyst, Production Supervisors, Warehouse Operators / Technicians
3 September 2026
Sun Pharma Hiring QC Analyst, Production Supervisors, Warehouse Operators / Technicians
Soft Gelatin; Granulation; Compression; Wurster; Coating; Capsule; BQS; Cartonator. Sun Pharma
Pharma Job in OSD regulated plants at Amneal Pharmaceuticals
3 September 2026
Pharma Job in OSD regulated plants at Amneal Pharmaceuticals
Supervise and execute manufacturing activities in Granulation, Coating, Compression, and Capsulation as per cGMP and approved SOPs; Operate and monitor manufacturing equipment, ensuring proper batch setting, material handling, cleaning, and equipment performance, Amneal Pharmaceuticals
Eikomp Looking for CDSCO Regulatory Associate
3 September 2026
Eikomp Looking for CDSCO Regulatory Associate
Lead ISI Mark and CRS certification projects from application to grant. Prepare and review all documentation for BIS portal submissions. Coordinate product testing with BIS-recognized laboratories
Torrent Pharma Hiring QC Executive / Technical Assistant
3 September 2026
Torrent Pharma Hiring QC Executive / Technical Assistant
Having sound knowledge of Operation. Troubleshooting of QC Instruments & Investigation of OOS /OOT/Deviation. (e.g HPLC, GC, UV, FTIR, Polarimeter, UV-Spectrophotometer, KF, Apparatus)
Granules India Interview - Jobs in Technology Transfer, Quality Control, Formulation
3 September 2026
Granules India Interview - Jobs in Technology Transfer, Quality Control, Formulation
Develop, maintain, and update laboratory systems and documentation, including SOPs, IQ/OQ/PQ documents, training records, and related quality documents. 
Gland Pharma’s Visakhapatnam Facilities Clear USFDA Inspection With Zero Observations
3 September 2026
Gland Pharma’s Visakhapatnam Facilities Clear USFDA Inspection With Zero Observations

Gland Pharma Limited has announced the successful conclusion of a routine Good Manufacturing Practice (GMP) inspection conducted by the United States Food and Drug Administration (USFDA) at its facilities in Visakhapatnam.

The inspection was carried out at the company’s VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam. The regulatory inspection commenced on August 24, 2026, and concluded on September 1, 2026.

VEGFR Inhibitors Show Strong Pancreatic Tumor Control in Metastatic Kidney Cancer Study
3 September 2026
VEGFR Inhibitors Show Strong Pancreatic Tumor Control in Metastatic Kidney Cancer Study

A new study published in Acta Clinica Belgica has found that vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) can produce substantial tumor shrinkage in patients with metastatic clear-cell renal cell carcinoma (ccRCC) involving the pancreas.

Adalimumab Emerges as Most Cost-Efficient Biologic for Hidradenitis Suppurativa, Study Finds
3 September 2026
Adalimumab Emerges as Most Cost-Efficient Biologic for Hidradenitis Suppurativa, Study Finds
A new economic evaluation published in JAMA Dermatology has found that adalimumab 40 mg administered weekly offers the most consistent balance between treatment effectiveness and cost among currently approved monoclonal antibody therapies for hidradenitis suppurativa (HS).
ARPA-H Backs 125 Million USD Drive to Enable On-Demand Manufacturing of Personalized RNA Medicines
3 September 2026
ARPA-H Backs 125 Million USD Drive to Enable On-Demand Manufacturing of Personalized RNA Medicines

The Advanced Research Projects Agency for Health (ARPA-H) has selected five research teams to develop new technologies aimed at making individualized, RNA-based genetic medicines faster and more accessible.

The initiative is part of ARPA-H’s Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, which could receive up to 125 million USD in research and development funding. The program seeks to establish an automated, distributed manufacturing network capable of producing genetic medicines on demand and closer to the point of care.